About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Panel Discussion on MASLD Management, SGLT2 inhibitors, Obesity and Sleep Apnea
By
MUSC Cardiology
FEATURING
Andrew Schreiner
,
Chakradhari Inampudi
,
Gregory Jackson
By
MUSC Cardiology
FEATURING
Andrew Schreiner
,
Chakradhari Inampudi
,
Gregory Jackson
8 views
March 26, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Related Content
AUTOPLAY
ON
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
Feat.
S. Inzucchi
11:37
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…
Feat.
P. Heidenreich
11:25
ACC 2023 Conference Coverage
ACC 2023: SGLT2i Use - Dos and Don'ts
Feat.
A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century …
Feat.
R. DeFronzo
15:06
Robert Busch
GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!
26:01
Cardiology Fiesta 2017
Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…
Feat.
R. DeFronzo
37:21
University of Colorado Department of Medicine
Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…
Feat.
R. Johnson
17:44
Rita Jermyn
SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease
27:24
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
Feat.
L. Sloan
14:19
UChicago Medicine
S-QUAD Therapy and Beyond: HFpEF in 2024
Feat.
M. Belkin
19:30
ACC 2022 Conference Coverage
Hot Topics in Heart Failure ACC.22
Feat.
N. Ibrahim
10:02
Emory Diabetes Education Training Academy
Insulin Treatment in Patients with Type 2 Diabetes: When to Use Comb…
Feat.
G. Umpierrez
13:42
George Bakris
Current Status of Prevention and Treatment of Diabetic Nephropathy
13:43
Stanford Medicine
What's the Ideal Therapy for Obesity?
Feat.
A. Yeoh
34:04
The Texas Heart Institute
Use of Finerenone in Patients with Diabetes Who Have Kidney Disease
Feat.
G. Bakris
11:50
American Heart & Vascular Institute
New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …
Feat.
M. Kittleson
27:52
Top Ten Topics in Clinical Cardiology 2023
Medical Management of Diastolic Dysfunction: Does The Emperor Finall…
Feat.
S. Pinney
22:48
Scripps Health
Heart Failure with Preserved Ejection Fraction: New Treatments
Feat.
R. C. Mohan
14:02
Georgia Heart Institute
Heart Failure Therapies
Feat.
U. Egolum,
H. Samady
15:25
Javed Butler
SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus
